Twenty Sprague-Dawley rats weighing 280–300 g were divided into two groups often animals each.They were treated by daily submucosal injections of 50 µg prostaglandin E2 (PGE2) per kilogram body weight into the region below the apex of the left first maxillary molar (experimental) or vehicle into the region below the apex of the right first molar (control), for a period of 5 days.The animals of the first group were sacrificed immediately following the treatment period, while those of the second group were sacrificed 5 days after the treatment period.Twenty-two hours prior to sacrifice, a piece of latex orthodontic elastic was secured to the adjacent area between the first and second maxillary molars of both sides of each rat by using two mosquito hemostats.The periodontál ligament (PDL) mesial to the mesiobuccal root of the first maxillary molar was assayed for changes in PDL cell factors. The results showed that immediately following the 5-day treatment period the left PDL had a significant decrease in the total number of fibroblasts and a significant increase in the total number of both osteoclasts and nuclei per osteoclast, while no significant changes in the osteoblasts when compared with those of the right control PDL. The left PDL of animals which were sacrificed 5 days after the treatment period revealed a significant decrease in the number of total fibroblasts and only a slight decrease in both numbers of total osteoclasts and total nuclei per osteoclast, but again no significant changes in osteoblasts when compared with those of the right control PDL. The reduction in the number of total fibroblasts in the left PDL was attributable to the submucosal injection of PGE2 which probably inhibited mitoses of fibroblasts. In addition, submucosal injection of PGE2 might also have induced transformation of monocytes into osteoclasts and an increase in the osteoclast-resorptive activity, although its effect is short-acting. All the above findings demonstrated that treatment with 50 µg PGE2/kg/day for 5 consecutive days inhibited the proliferation of PDL fibroblasts and activated alveolar bone resorption during orthodontic tooth movement.

Keywords:
Prostaglandin E2, Periodontál ligament, Alveolar bone resorption, Bone cell, Fibroblast
This content is only available via PDF.
© 1988 S. Karger AG, Basel
1988
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.